Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 23 12:20PM ET
24.86
Dollar change
-0.28
Percentage change
-1.11
%
IndexRUT P/E- EPS (ttm)-4.24 Insider Own5.28% Shs Outstand124.20M Perf Week-0.56%
Market Cap3.09B Forward P/E- EPS next Y-2.71 Insider Trans-3.57% Shs Float117.64M Perf Month6.75%
Income-470.79M PEG- EPS next Q-0.52 Inst Own77.22% Short Float8.17% Perf Quarter-21.31%
Sales35.47M P/S87.05 EPS this Y-59.65% Inst Trans-1.58% Short Ratio7.94 Perf Half Y-12.37%
Book/sh3.90 P/B6.38 EPS next Y11.53% ROA-50.99% Short Interest9.61M Perf Year-31.47%
Cash/sh4.21 P/C5.90 EPS next 5Y7.33% ROE-101.18% 52W Range20.67 - 39.83 Perf YTD-18.75%
Dividend Est.- P/FCF- EPS past 5Y-24.19% ROI-53.60% 52W High-37.58% Beta0.96
Dividend TTM- Quick Ratio8.31 Sales past 5Y205.96% Gross Margin55.12% 52W Low20.28% ATR (14)1.24
Dividend Ex-Date- Current Ratio8.31 EPS Y/Y TTM-197.97% Oper. Margin-1335.58% RSI (14)51.98 Volatility3.77% 5.21%
Employees525 Debt/Eq0.83 Sales Y/Y TTM-87.00% Profit Margin-1327.18% Recom1.57 Target Price52.38
Option/ShortYes / Yes LT Debt/Eq0.82 EPS Q/Q-325.79% Payout- Rel Volume0.30 Prev Close25.14
Sales Surprise-100.00% EPS Surprise-116.15% Sales Q/Q-100.00% EarningsMay 09 AMC Avg Volume1.21M Price24.86
SMA203.93% SMA50-1.49% SMA200-11.56% Trades Volume166,185 Change-1.11%
Date Action Analyst Rating Change Price Target Change
Dec-04-23Initiated BofA Securities Buy $29
Sep-19-23Initiated Citigroup Neutral $33
Jul-21-23Initiated TD Cowen Outperform
May-12-23Downgrade SVB Securities Outperform → Market Perform $40
Apr-26-23Initiated SMBC Nikko Outperform $80
Apr-12-23Upgrade SVB Securities Market Perform → Outperform $21 → $35
Mar-21-23Initiated Bernstein Mkt Perform $27
Sep-09-22Initiated Morgan Stanley Equal-Weight $41
May-11-22Upgrade Robert W. Baird Neutral → Outperform $71 → $60
Jan-19-22Resumed Goldman Buy $90 → $85
May-20-24 11:04AM
06:00AM
May-14-24 07:08AM
May-10-24 01:03PM
12:26PM
11:32AM Loading…
11:32AM
May-09-24 11:54PM
04:34PM
04:14PM
04:01PM
May-03-24 07:26AM
May-02-24 04:01PM
Apr-29-24 07:30AM
Apr-26-24 07:30AM
Apr-24-24 04:01PM
07:30AM Loading…
07:30AM
Apr-16-24 09:00AM
Apr-07-24 09:00AM
Apr-04-24 01:27AM
Apr-01-24 04:30PM
Mar-25-24 08:00AM
Mar-11-24 06:53PM
Mar-08-24 11:29PM
07:30AM
Mar-04-24 07:30AM
Feb-07-24 10:42AM
10:02AM
Feb-06-24 04:32PM
04:32PM
04:01PM
04:01PM Loading…
Jan-22-24 04:01PM
Jan-18-24 05:37AM
Jan-09-24 03:02AM
Jan-06-24 01:01PM
Jan-05-24 05:00PM
11:02AM
Jan-03-24 07:00AM
Dec-29-23 04:01PM
Dec-24-23 09:01AM
Dec-21-23 07:30AM
Dec-20-23 07:30AM
Dec-01-23 09:32AM
Nov-30-23 12:22PM
Nov-29-23 04:51PM
04:01PM
Nov-28-23 07:30AM
Nov-22-23 09:46PM
Nov-21-23 04:01PM
Nov-16-23 07:30AM
Nov-13-23 09:30AM
Nov-06-23 07:30AM
Nov-02-23 07:30AM
Oct-31-23 08:30AM
07:46AM
Oct-28-23 05:02AM
Oct-03-23 04:01PM
Sep-27-23 04:30PM
Sep-21-23 05:01AM
Sep-11-23 07:30AM
Sep-09-23 03:59PM
Sep-07-23 07:34PM
Sep-01-23 07:30AM
Aug-13-23 08:32AM
Aug-10-23 08:10AM
Aug-08-23 09:42AM
09:13AM
06:20AM
Aug-07-23 04:16PM
04:01PM
Jul-24-23 04:00PM
Jul-17-23 07:30AM
Jul-06-23 04:30PM
Jun-30-23 06:52AM
Jun-27-23 07:30AM
Jun-24-23 08:15AM
Jun-21-23 08:00PM
Jun-14-23 06:34PM
Jun-06-23 07:30AM
Jun-01-23 04:07PM
07:30AM
07:07AM
May-23-23 07:30AM
May-16-23 07:30AM
May-15-23 04:00PM
May-11-23 09:27AM
May-10-23 06:25AM
May-04-23 06:24AM
May-02-23 04:17PM
04:01PM
Apr-26-23 08:00PM
07:06AM
Apr-25-23 01:19PM
11:20AM
07:30AM
Apr-18-23 07:30AM
Apr-17-23 08:17AM
Apr-16-23 05:21AM
Apr-12-23 07:30AM
Apr-04-23 04:30PM
07:30AM
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vakiener VictoriaDirectorMay 02 '24Sale23.311,79941,93530,205May 06 06:04 PM
Hamilton James CChief Discovery/Trans MedicineApr 01 '24Sale28.036,000168,180204,851Apr 03 06:05 PM
Lu HongboDirectorMar 20 '24Buy27.501,00027,50033,680Mar 20 07:06 PM
Lu HongboDirectorMar 19 '24Buy28.001,00028,00032,680Mar 20 07:06 PM
Lu HongboDirectorMar 18 '24Buy27.491,00027,49031,680Mar 20 07:06 PM
Myszkowski Kenneth AllenChief Financial OfficerMar 06 '24Sale35.1940,0001,407,600400,600Mar 08 05:54 PM
Anzalone Christopher RichardChief Executive OfficerJan 31 '24Option Exercise14.5457,499836,0353,772,547Feb 02 05:25 PM
Anzalone Christopher RichardChief Executive OfficerJan 31 '24Sale32.3557,4991,860,0193,715,048Feb 02 05:25 PM
Hamilton James CChief Discovery/Trans MedicineJan 12 '24Sale36.897,940292,904210,851Jan 17 06:32 PM
Vakiener VictoriaDirectorJan 11 '24Sale38.104,720179,81332,001Jan 16 06:06 PM
Waddill William D.DirectorJan 11 '24Sale38.073,934149,75947,870Jan 16 06:06 PM
Ferrari MauroDirectorJan 11 '24Sale38.063,147119,78760,778Jan 16 06:06 PM
GIVEN DOUGLAS BDirectorJan 11 '24Sale38.062,911110,788129,711Jan 16 06:06 PM
Hamilton James CChief Discovery/Trans MedicineJan 05 '24Sale35.1832,1431,130,748218,791Jan 05 08:02 PM
O'Brien PatrickCOO and General CounselJan 05 '24Sale35.2722,841805,716464,385Jan 05 07:58 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 05 '24Sale35.2716,104567,910440,600Jan 08 05:16 PM
San Martin JavierChief Medical OfficerJan 05 '24Sale35.268,303292,804198,497Jan 08 05:16 PM
Oliver TracieChief Commercial OfficerJan 05 '24Sale33.89742,508136,501Jan 08 05:17 PM
O'Brien PatrickCOO and General CounselJan 04 '24Sale32.631,60052,208402,226Jan 05 07:58 PM
O'Brien PatrickCOO and General CounselJan 03 '24Sale32.288,749282,439403,826Jan 05 07:58 PM
Hamilton James CChief Discovery/Trans MedicineJan 03 '24Sale32.196,300202,781175,934Jan 05 08:02 PM
Anzalone Christopher RichardChief Executive OfficerJan 02 '24Sale31.019,952308,6373,715,048Jan 04 05:25 PM
Anzalone Christopher RichardChief Executive OfficerDec 20 '23Sale28.5412,000342,4803,725,000Dec 22 05:04 PM
San Martin JavierChief Medical OfficerNov 20 '23Sale28.8019,700567,315131,800Nov 22 02:31 PM
Anzalone Christopher RichardChief Executive OfficerOct 25 '23Sale24.2124,338589,2233,737,000Oct 27 06:23 PM
Vakiener VictoriaDirectorSep 28 '23Sale26.331,55040,81221,734Oct 02 05:51 PM
Anzalone Christopher RichardChief Executive OfficerSep 18 '23Option Exercise4.7557,755274,3363,819,093Sep 20 06:10 PM
Anzalone Christopher RichardChief Executive OfficerSep 18 '23Sale28.1257,7551,624,2233,761,338Sep 20 06:10 PM
Oliver TracieChief Commercial OfficerJul 03 '23Sale35.318,925315,14261,575Jul 06 06:04 PM
Hamilton James CChief Discovery/Trans MedicineJun 30 '23Sale35.533,000106,590188,484Jul 05 06:15 PM
Myszkowski Kenneth AllenChief Financial OfficerJun 27 '23Sale36.2015,000543,000381,704Jun 29 06:41 PM